NasdaqGM:ARDX

Stock Analysis Report

Executive Summary

Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.

Risks

  • Ardelyx has significant price volatility in the past 3 months.

Share Price & News

How has Ardelyx's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-19.3%

NasdaqGM:ARDX

0.6%

US Biotechs

0.8%

US Market


1 Year Return

14.1%

NasdaqGM:ARDX

-10.2%

US Biotechs

1.9%

US Market

ARDX outperformed the Biotechs industry which returned -9.7% over the past year.

ARDX outperformed the Market in United States of America which returned 2.1% over the past year.


Share holder returns

ARDXIndustryMarket
7 Day-19.3%0.6%0.8%
30 Day57.6%-0.8%3.4%
90 Day80.0%-0.5%2.1%
1 Year14.1%14.1%-9.4%-10.2%4.2%1.9%
3 Year-60.9%-60.9%6.0%2.4%46.7%37.2%
5 Year-66.8%-66.8%5.0%-0.09%62.3%44.5%

Price Volatility Vs. Market

How volatile is Ardelyx's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Ardelyx undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Ardelyx's share price is below the future cash flow value, and at a moderate discount (> 20%).

Ardelyx's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

Ardelyx is loss making, we can't compare its value to the US Biotechs industry average.

Ardelyx is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Ardelyx, we can't assess if its growth is good value.


Price Based on Value of Assets

Ardelyx is overvalued based on assets compared to the US Biotechs industry average.


Next Steps

Future Growth

How is Ardelyx expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

58.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Ardelyx's revenue is expected to grow significantly at over 20% yearly.

Ardelyx's earnings are expected to grow significantly at over 20% yearly.

Ardelyx's revenue growth is expected to exceed the United States of America market average.

Ardelyx's earnings growth is expected to exceed the United States of America market average.

Ardelyx's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Ardelyx will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Ardelyx performed over the past 5 years?

-32.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Ardelyx does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Ardelyx's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Ardelyx's 1-year growth to the US Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Ardelyx has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Ardelyx has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Ardelyx improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Ardelyx's financial position?


Financial Position Analysis

Ardelyx is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Ardelyx's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Ardelyx's level of debt (72.3%) compared to net worth is high (greater than 40%).

Unable to establish if Ardelyx's debt level has increased without past 5-year debt data.


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.6x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Ardelyx has sufficient cash runway for 1.4 years based on current free cash flow.

Ardelyx has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of -12.4% each year.


Next Steps

Dividend

What is Ardelyx's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Ardelyx's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Ardelyx's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Ardelyx has not reported any payouts.

Unable to verify if Ardelyx's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Ardelyx has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Ardelyx's salary, the management and board of directors tenure and is there insider trading?

5.3yrs

Average management tenure


CEO

Mike Raab (54yo)

10.5yrs

Tenure

US$4,182,246

Compensation

Mr. Michael G. Raab, also known as Mike, has been the Chief Executive Officer and President of Ardelyx, Inc. since March 2009. He is a Director of Tempest Therapeutics Inc. since May 2019. Mr. Raab was a V ...


CEO Compensation Analysis

Mike's remuneration is higher than average for companies of similar size in United States of America.

Mike's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

5.3yrs

Average Tenure

55yo

Average Age

The average tenure for the Ardelyx management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

4.4yrs

Average Tenure

54yo

Average Age

The tenure for the Ardelyx board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$7,25807 Jun 19
David Rosenbaum
EntityIndividual
Role
Senior Key Executive
Chief Development Officer
Shares2,856
Max PriceUS$2.54
SellUS$25,55107 Jun 19
Michael Raab
EntityIndividual
Role
Chief Executive Officer
President
Shares10,054
Max PriceUS$2.54
SellUS$8,55107 Jun 19
Mark Kaufmann
EntityIndividual
Role
Chief Financial Officer
CFO & Treasurer
Shares3,357
Max PriceUS$2.55
SellUS$6,40407 Jun 19
Elizabeth Grammer
EntityIndividual
Role
Chief Legal Officer
Executive VP
Shares2,520
Max PriceUS$2.54
SellUS$10,86605 Jan 19
David Rosenbaum
EntityIndividual
Role
Senior Key Executive
Chief Development Officer
Shares6,386
Max PriceUS$1.70
SellUS$33,41805 Jan 19
Michael Raab
EntityIndividual
Role
Chief Executive Officer
President
Shares19,644
Max PriceUS$1.70
SellUS$11,15405 Jan 19
Mark Kaufmann
EntityIndividual
Role
Chief Financial Officer
CFO & Treasurer
Shares6,556
Max PriceUS$1.70
SellUS$8,37005 Jan 19
Elizabeth Grammer
EntityIndividual
Role
Chief Legal Officer
Executive VP
Shares4,920
Max PriceUS$1.70
SellUS$18,57115 Nov 18
Elizabeth Grammer
EntityIndividual
Role
Chief Legal Officer
Executive VP
Shares6,539
Max PriceUS$2.84
SellUS$18,57115 Nov 18
Michael Raab
EntityIndividual
Role
Chief Executive Officer
President
Shares6,539
Max PriceUS$2.84
SellUS$18,57115 Nov 18
Mark Kaufmann
EntityIndividual
Role
Chief Financial Officer
CFO & Treasurer
Shares6,539
Max PriceUS$2.84
SellUS$15,81915 Nov 18
David Rosenbaum
EntityIndividual
Role
Senior Key Executive
Chief Development Officer
Shares5,570
Max PriceUS$2.84
SellUS$1,76713 Nov 18
Rising River Partners, L.P.
EntityCompany
Shares592
Max PriceUS$2.98

Ownership Breakdown


Management Team

  • Mike Raab (54yo)

    President

    • Tenure: 10.5yrs
    • Compensation: US$4.18m
  • Liz Grammer (55yo)

    Executive VP

    • Tenure: 5.3yrs
    • Compensation: US$1.69m
  • Mark Kaufmann (51yo)

    CFO & Treasurer

    • Tenure: 5.3yrs
    • Compensation: US$799.18k
  • David Rosenbaum (58yo)

    Chief Development Officer

    • Tenure: 2.7yrs
    • Compensation: US$1.71m
  • Rob Blanks

    Senior Vice President of Regulatory Affairs & Quality Assurance

    • Tenure: 0yrs
  • Jeff Jacobs (56yo)

    Senior Vice President of Technical Operations

    • Tenure: 4.7yrs
  • Kimia Keshtbod

    Manager of Corporate Communications & Investor Relations

    • Tenure: 0yrs

Board Members

  • Dave Mott (54yo)

    Chairman

    • Tenure: 5.5yrs
    • Compensation: US$127.21k
  • Gordon Ringold (68yo)

    Independent Director

    • Tenure: 5.3yrs
    • Compensation: US$91.21k
  • Rob Bazemore (51yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: US$90.71k
  • Bill Bertrand (54yo)

    Independent Director

    • Tenure: 3.9yrs
    • Compensation: US$93.21k
  • Jan Lundberg (65yo)

    Director

    • Tenure: 1.5yrs
    • Compensation: US$177.50k
  • Mike Raab (54yo)

    President

    • Tenure: 10.5yrs
    • Compensation: US$4.18m
  • Rick Rodgers (52yo)

    Independent Director

    • Tenure: 5.5yrs
    • Compensation: US$110.71k
  • Geoff Block (53yo)

    Director

    • Tenure: 0.5yrs
  • Annalisa Jenkins (54yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: US$97.21k

Company Information

Ardelyx, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Ardelyx, Inc.
  • Ticker: ARDX
  • Exchange: NasdaqGM
  • Founded: 2007
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$293.908m
  • Shares outstanding: 62.80m
  • Website: https://www.ardelyx.com

Number of Employees


Location

  • Ardelyx, Inc.
  • 34175 Ardenwood Boulevard
  • Suite 200
  • Fremont
  • California
  • 94555
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ARDXNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDJun 2014
41XDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2014

Biography

Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company’s lead product candidat ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 01:19
End of Day Share Price2019/09/17 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.